1. Generics Bulletin

Krka’s EBITDA Margin Slumps Despite Record H1 Sales

Follows Russian Inventory Purchases Necessary For Long-Term Supply

 
• By Dean Rudge

Krka has explained a near double-digit percentage point drop for its EBITDA margin, as it presented preliminary results for the first half of 2022.

Russia map close up with magnifier
Russia is Krka's largest individual market • Source: Shutterstock

Krka Group’s EBITDA margin is to plummet by more than nine percentage points as reported for the first half of 2022, from 31.5% to 22.4%, as a result of the Slovenian firm increasing inventories of raw materials, materials, bulk products, and products required for “long-term uninterrupted supply of Krka’s pharmaceuticals in the Russian market.”

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Speranza Starts Generics Offshoot In Response To Wider US Pharma Manufacturing Drive

 
• By Adam Zamecnik

Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.